Bone Marrow Mesenchymal Stem Cells from Healthy Donors and Sporadic Amyotrophic Lateral Sclerosis Patients

Cell Transplantation

Article

Lucia Testa¹  Gaia Donata Oggioni¹  Nicola Nasuelli¹  Letizia Mazzini¹  Deborah Rustichelli²  Katia Mareschi²  Monica Gunetti²  Ivana Ferrero²  Franca Fagioli² 

[1] Department of Neurology, “Maggiore della Carità Hospital”, University of Eastern Piedmont, Novara, Italy;Department of Pediatrics, “Regina Margherita Children's Hospital”, University of Turin, Turin, Italy;

关键词: Amyotrophic lateral sclerosis;    Mesenchymal stem cells;    In vitro expansion;    Cellular therapy;   

DOI  :  10.3727/096368908784153940

 received in 2007-03-20, accepted in 2007-08-31,  发布年份 2008

来源: Sage Journals

【 摘 要 】

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease lacking effective therapies. Cell replacement therapy has been suggested as a promising therapeutic approach for multiple neurodegenerative diseases, including motor neuron disease. We analyzed expanded mesenchymal stem cells (MSCs) isolated from sporadic ALS patients and compared them with MSCs isolated from healthy donors. MSCs were isolated from bone marrow by Percoll gradient and maintained in culture in MSC Medium until the third passage. Growth kinetics, immunophenotype, telomere length, and karyotype were evaluated during in vitro expansion. Osteogenic, adipogenic, chondrogenic, and neurogenic differentiation potential were also evaluated. No morphological differences were observed in the MSCs isolated from donors or patients. The cellular expansion potential of MSCs from donors and patients was slightly different. After three passages, the MSCs isolated from donors reached a cumulative population doubling higher than from patients but the difference was not statistically significant. No significant differences between donors or patients were observed in the immunophenotype analysis. No chromosomal alteration or evidence of cellular senescence was observed in any samples. Both donor and patient MSCs, after exposure to specific conditioning media, differentiated into adipocytes, osteoblasts, chondrocytes, and neuron-like cells. These results suggest that extensive in vitro expansion of patient MSCs does not involve any functional modification of the cells, including chromosomal alterations or cellular senescence. Hence, there is a good chance that MSCs might be used as a cell-based therapy for ALS patients.

【 授权许可】

Unknown   
© 2008 Cognizant Comm. Corp.